U.S., Dec. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07279584) titled 'Golidocitinib Combined With GemOx in RR PTCL' on Dec. 01.
Brief Summary: The objective of this study is to evaluate the efficacy and safety of golidocitinib in combination with the GemOx regimen in r/r PTCL
Study Start Date: Dec. 20
Study Type: INTERVENTIONAL
Condition:
Peripheral T-cell Lymphomas (PTCL)
Intervention:
DRUG: golidocitinib
150mg qd po
DRUG: GEMOX
Gemcitabine: 1000mg/m2, d1; Oxaliplatin:100mg/m2, d1
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Ruijin Hospital
Information provided by (Responsible Party): Zhao Weili, Ruijin Hospital
Published by HT Digital Content Services with permission from Health Dail...